Lee Kyoo-Hyung, Choi Seong-Jun, Lee Jung-Hee, Lee Jung-Shin, Kim Woo-Kun, Lee Kyu-Bo, Sohn Sang-Kyun, Kim Jong-Gwang, Kim Dong-Hwan, Seol Miee, Lee Young-Shin, Lee Je-Hwan
Hematology Section, Department of Internal Medicine, University of Ulsan, College of Medicine, Asan Medical Center, Seoul, Korea.
Haematologica. 2005 Jul;90(7):939-48.
Current grading systems of acute graft-versus-host disease (GVHD) cannot effectively identify patients with poor prognosis at the onset of acute GVHD after allogeneic hematopoietic cell transplantation.
In a retrospective analysis, we evaluated the prognostic value of various clinical parameters at the initiation of treatment in 83 patients who developed systemic treatment-requiring acute GVHD after allogeneic hematopoietic cell transplantation.
Forty-three of 83 patients (52%) experienced initial treatment failure (40 required secondary treatment due to lack of response and 3 died) and 43 (52%) experienced treatment success, defined as completion of treatment (initial and, if given, secondary) within 100 days. The GVHD-specific survival rate was 65.5%, with 27 deaths due to GVHD-related complications without relapse of underlying malignancies within 1 year. HLA-mismatched transplantation, visceral initiation, and peripheral blood lymphocytopenia ( pound100/mL) were independent variables predicting higher initial treatment failure (Odd ratios (OR)=12.225, 12.036, and 7.481, respectively). The above variables and initial acute GVHD grade III-IV vs. II were independent variables predicting shorter GVHD-specific survival (OR=0.322, 0.247, 0.340, and 0.385, respectively). High-risk disease status, visceral initiation, and hypoalbuminemia ( pound2.8 g/dL) were independent variables predicting lower treatment success (OR=0.221, 0.162, and 0.270, respectively). The predictive value of visceral initiation and lymphocytopenia for GVHD-specific survival was verified in an independent cohort of 58 patients.
Lymphocytopenia and hypoalbuminemia may be useful baseline prognostic factors for acute GVHD after allogeneic hematopoietic cell transplantation.
目前的急性移植物抗宿主病(GVHD)分级系统无法在异基因造血细胞移植后急性GVHD发病时有效识别预后不良的患者。
在一项回顾性分析中,我们评估了83例异基因造血细胞移植后发生需要全身治疗的急性GVHD患者在治疗开始时各种临床参数的预后价值。
83例患者中有43例(52%)初次治疗失败(40例因无反应需要二次治疗,3例死亡),43例(52%)治疗成功,定义为在100天内完成治疗(初次治疗以及若有则包括二次治疗)。GVHD特异性生存率为65.5%,1年内有27例死于GVHD相关并发症且无潜在恶性肿瘤复发。HLA不匹配移植、内脏受累起始以及外周血淋巴细胞减少(≤100/mL)是预测初次治疗失败率较高的独立变量(比值比(OR)分别为12.225、12.036和7.481)。上述变量以及初次急性GVHD III - IV级与II级相比是预测GVHD特异性生存期较短的独立变量(OR分别为0.322、0.247、0.340和0.385)。高危疾病状态、内脏受累起始以及低白蛋白血症(≤2.8 g/dL)是预测治疗成功率较低的独立变量(OR分别为0.221、0.162和0.270)。在内脏受累起始和淋巴细胞减少对GVHD特异性生存的预测价值在一个58例患者的独立队列中得到验证。
淋巴细胞减少和低白蛋白血症可能是异基因造血细胞移植后急性GVHD有用的基线预后因素。